Phase I Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors With c-Met Abnormalities
Latest Information Update: 18 May 2024
At a glance
- Drugs SPH 3348 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 11 May 2024 Planned End Date changed from 30 Mar 2024 to 30 Dec 2024.
- 11 May 2024 Planned primary completion date changed from 30 Mar 2024 to 30 Jul 2024.
- 03 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Mar 2024.